The FDA placed a clinical hold on the IND application for the company Aardvark.
5 reports, 2 independent
Updated Sep 10
Gone quiet
- Reports
- 5
- Developments
- 2
- Repetition
- 60%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
The FDA placed a clinical hold on the IND application for the company Aardvark.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.FDA placed a full clinical hold on Aardvark's drug ARD-101.1 source
FDA places clinical hold on Aardvark's IND application.1 source
Keep exploring
The entities involved
Related events
- FDA removed the clinical hold on Arbutus Biopharma Corporation's IND application, allowing potential clinical development.
- FDA approval expands patient access to therapies for ACCORD.
- Litigation regarding FDA approval process.
- FDA communicated eligibility for accelerated approval for ProKidney Corp., which plans to present study results at ASN.
- Arthur Caplan questioned the FDA regarding the status of clinical trials in 2006.